Cross-document analysis of Velorant safety data — 5 documents, October 2024 data lock
| Signal (MedDRA PT) | Incidence | vs. Class average | Status |
|---|
ERA class average derived from Ambrisenpar SmPC Rev.7 §4.8, Macitenbar EU SmPC Rev.4 §4.8, and Riocibinol EU SmPC §4.8. Click the Hypotension row to view temporal analysis.